ASCO 2024: Artificial intelligence-based patient navigator may help improve disparities in colon cancer screening
An artificial intelligence-based patient navigator tool demonstrated improved potential in helping to overcome patient attrition…
Browsing: ASCO
ASCO 2024: Asciminib may be safer, more effective treatment option for patients with newly diagnosed chronic myeloid leukaemia
A new study found asciminib to be a potentially safer and more effective treatment option…
ASCO 2024: Oestrogen-only hormone therapy may increase cancer risk while oestrogen-progestin combination may lower risk
For people who have been through menopause and have taken menopausal hormone therapy, conjugated equine…
ASCO 2024: Combination therapy significantly improves outcomes for patients with metastatic colorectal cancer
A study led by UCLA Health Jonsson Comprehensive Cancer Center researchers found that using a combination of experimental immunotherapy drugs…
ASCO 2024: Most young women treated for breast cancer can have children
New research by Dana-Farber Cancer Institute (USA) investigators has encouraging news for young women who…
ASCO GU 2024: Study shows positive results for patients with muscle-invasive urothelial carcinoma
Patients with muscle-invasive urothelial cancer and a high risk of recurrence after surgery may have…
ASCO GU 2024: Subcutaneous nivolumab as effective as IV for renal cell carcinoma with much faster treatment time
Subcutaneous injection of the immunotherapy nivolumab is non-inferior to intravenous delivery and dramatically reduces treatment…
ASCO GI 2024: Dual immunotherapy treatment improves progression-free survival in certain patients with advanced colorectal cancer
The dual immunotherapy combination of nivolumab and ipilimumab reduced the risk of disease progression or…
ASCO GI 2024: New study adds to ambiguity of role of post-operative ctDNA to guide treatment in patients with low-risk, stage IIA colon cancer
The role of ctDNA, or liquid biopsy, as a predictive tool to guide and monitor…
ASCO GI 2024: New immunotherapy combinations for patients with oesophageal cancer
Results from a new phase III study found that combining PD-L1 and TIGIT inhibitors plus…